A major cause of ocular morbidity in the United States is lacrimal insufficiency, which affects 10 million Americans, primarily women. Approximately one fifth of these cases are clearly autoimmune- mediated and accompanied by additional symptoms which lead to the diagnosis of Sjogren's syndrome. The remainder of cases, designated as Non-Sjogren's lacrimal insufficiency, may also be mediated by the immune system. In the lacrimal gland, defects in membrane trafficking including altered processing of internalized and newly synthesized constituents through the endocytic and secretory pathways have been proposed to contribute to the development of dry eye and the autoimmune disease Sjogren's syndrome. Despite the hypothesis that defective trafficking plays a role in production of autoantigens in the lacrimal gland, little is known about the precise mechanisms by which altered trafficking patterns might occur. In interphase cells, microtubules provide a network which supports the movement of membranes driven by two different cytoplasmic motor proteins, kinesin and cytoplasmic dynein. Despite their importance in membrane trafficking, little is known about the involvement of these motors in normal and defective trafficking in the lacrimal gland. The PI has explored the membrane association and in vitro properties of kinesin from lacrimal acinar cells. Preliminary data suggest that kinesin plays a role in secretion under conditions that represent normal function and also under conditions in which traffic has been altered by sustained stimulation. Since such conditions may underlie the initiation of local autoimmune responses that may progress to Sjogren's syndrome or non- Sjogren's lacrimal insufficiency, these findings necessitate a more comprehensive investigation of the role of microtubule-based transport and specifically, kinesin, in lacrimal acinar membrane trafficking. The focus of this proposal is therefore: a. To identify the changes in lacrimal acinar membrane trafficking caused by disruption of microtuble-based motility. b. To define the biochemical properties and membrane interactions of kinesin isolated from lacrimal acinar cells. c. To determine whether stimulation of lacrimal secretion by carbachol, a secretagogue acting through diacylglycerol and Ca2+ -dependent pathways, alters kinesin activity. Once the function of kinesin is defined in resting and stimulated cells from normal rabbits, the PI may begin to question whether kinesin activity is altered in isolated acini from a recently described rabbit model of autoimmune dacryadenitis which exhibits features of Sjogren's syndrome.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
2R01EY011386-04
Application #
2902575
Study Section
Visual Sciences A Study Section (VISA)
Program Officer
Fisher, Richard S
Project Start
1996-07-01
Project End
2004-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
4
Fiscal Year
2000
Total Cost
$246,478
Indirect Cost
Name
University of Southern California
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Ju, Yaping; Janga, Srikanth Reddy; Klinngam, Wannita et al. (2018) NOD and NOR mice exhibit comparable development of lacrimal gland secretory dysfunction but NOD mice have more severe autoimmune dacryoadenitis. Exp Eye Res 176:243-251
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Klinngam, Wannita; Fu, Runzhong; Janga, Srikanth R et al. (2018) Cathepsin S Alters the Expression of Pro-Inflammatory Cytokines and MMP-9, Partially through Protease-Activated Receptor-2, in Human Corneal Epithelial Cells. Int J Mol Sci 19:
Janga, Srikanth R; Shah, Mihir; Ju, Yaping et al. (2018) Longitudinal analysis of tear cathepsin S activity levels in male non-obese diabetic mice suggests its potential as an early stage biomarker of Sjögren's Syndrome. Biomarkers :1-12
Edman, Maria C; Janga, Srikanth R; Meng, Zhen et al. (2018) Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sjögren's Syndrome patients. Sci Rep 8:11044
Hawley, Dillon; Tang, Xin; Zyrianova, Tatiana et al. (2018) Myoepithelial cell-driven acini contraction in response to oxytocin receptor stimulation is impaired in lacrimal glands of Sjögren's syndrome animal models. Sci Rep 8:9919
Meng, Zhen; Klinngam, Wannita; Edman, Maria C et al. (2017) Interferon-? treatment in vitro elicits some of the changes in cathepsin S and antigen presentation characteristic of lacrimal glands and corneas from the NOD mouse model of Sjögren's Syndrome. PLoS One 12:e0184781
Aluri, Hema S; Samizadeh, Mahta; Edman, Maria C et al. (2017) Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Tear Production in a Mouse Model of Sjögren's Syndrome. Stem Cells Int 2017:3134543
Shah, Mihir; Edman, Maria C; Reddy Janga, Srikanth et al. (2017) Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome. Invest Ophthalmol Vis Sci 58:372-385
Meng, Zhen; Edman, Maria C; Hsueh, Pang-Yu et al. (2016) Imbalanced Rab3D versus Rab27 increases cathepsin S secretion from lacrimal acini in a mouse model of Sjögren's Syndrome. Am J Physiol Cell Physiol 310:C942-54

Showing the most recent 10 out of 75 publications